Diagenode

The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs


Mandoli A. et al.

The t(8;21) acute myeloid leukemia (AML)-associated oncoprotein AML1-ETO disrupts normal hematopoietic differentiation. Here, we have investigated its effects on the transcriptome and epigenome in t(8,21) patient cells. AML1-ETO binding was found at promoter regions of active genes with high levels of histone acetylation but also at distal elements characterized by low acetylation levels and binding of the hematopoietic transcription factors LYL1 and LMO2. In contrast, ERG, FLI1, TAL1, and RUNX1 bind at all AML1-ETO-occupied regulatory regions, including those of the AML1-ETO gene itself, suggesting their involvement in regulating AML1-ETO expression levels. While expression of AML1-ETO in myeloid differentiated induced pluripotent stem cells (iPSCs) induces leukemic characteristics, overexpression increases cell death. We find that expression of wild-type transcription factors RUNX1 and ERG in AML is required to prevent this oncogene overexpression. Together our results show that the interplay of the epigenome and transcription factors prevents apoptosis in t(8;21) AML cells.

Tags
Bioruptor
Antibody

Share this article

Published
November, 2016

Source

Products used in this publication

  • ChIP-seq Grade
    C15310197
    AML1-ETO Antibody
  • cut and tag antibody icon
    C15410196
    H3K27ac Antibody
  • cut and tag antibody icon
    C15410195
    H3K27me3 Antibody
  • ChIP-seq Grade
    C15410192
    H3K36me3 Antibody
  • cut and tag antibody icon
    C15410194
    H3K4me1 Antibody
  • cut and tag antibody icon
    C15410003-50
    H3K4me3 Antibody
  • cut and tag antibody icon
    C15410193
    H3K9me3 Antibody
  • ChIP-seq Grade
    C15410005
    H3K9/14ac Antibody

Events

 See all events

 


       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy